Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 12Lymphoid 11Gastrointestinal 11Genitourinary 10CNS 9Other hematologic neoplasm 8Myeloid 7Breast 6Plasma cell 5Head & Neck 5Gynecologic 5Tumor-Agnostic 3Thoracic 3Endocrine 3NET 2Dermatologic 2Other neoplasm 1

Conditions

Ovarian Neoplasms 2Melanoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Wilms Tumor 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Hepatoblastoma 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Desmoid Tumors 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 24Specimen Handling 21Nivolumab 20Magnetic Resonance Spectroscopy 16Ipilimumab 12Biopsy 9Cyclophosphamide 5CTLA-4 Antigen 5relatlimab 4Opdualag 4HhAntag691 4trametinib 3fludarabine 3dabrafenib 3cemiplimab 3binimetinib 3avelumab 3aldesleukin 3Surgical Procedures, Operative 3Radiosurgery 3Paclitaxel 3Cisplatin 3Carboplatin 3talimogene laherparepvec 2omipalisib 2capivasertib 2atezolizumab 2X-Rays 2Taxes 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
X-Rays × Dermatologic × 30 days × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡